Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) Shares Outstanding (Weighted Average): 2020-2025

Historic Shares Outstanding (Weighted Average) for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $93.1 million.

  • Caribou Biosciences' Shares Outstanding (Weighted Average) rose 2.84% to $93.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.1 million, marking a year-over-year increase of 2.84%. This contributed to the annual value of $90.6 million for FY2024, which is 2.40% up from last year.
  • Caribou Biosciences' Shares Outstanding (Weighted Average) amounted to $93.1 million in Q3 2025, which was up 0.13% from $93.0 million recorded in Q2 2025.
  • Caribou Biosciences' Shares Outstanding (Weighted Average)'s 5-year high stood at $93.1 million during Q3 2025, with a 5-year trough of $51.2 million in Q1 2021.
  • Over the past 3 years, Caribou Biosciences' median Shares Outstanding (Weighted Average) value was $90.4 million (recorded in 2024), while the average stood at $85.5 million.
  • Data for Caribou Biosciences' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 47.33% (in 2024) over the last 5 years.
  • Over the past 5 years, Caribou Biosciences' Shares Outstanding (Weighted Average) (Quarterly) stood at $60.2 million in 2021, then rose by 1.84% to $61.3 million in 2022, then soared by 44.26% to $88.4 million in 2023, then rose by 2.40% to $90.6 million in 2024, then rose by 2.84% to $93.1 million in 2025.
  • Its last three reported values are $93.1 million in Q3 2025, $93.0 million for Q2 2025, and $93.0 million during Q1 2025.